TPOXX Approved for the Treatment of Human Smallpox Disease

By July 16, 2018

The approval was supported by findings from 12 clinical trials of TPOXX with more than 700 healthy volunteers that showed no drug-related serious adverse events.

FDA Grant Orphan Drug Status to Brincidofovir for Smallpox

By June 07, 2018

Brincidofovir is the Company's lead candidate, a nucleotide analog that has antiviral activity against variola virus, which causes smallpox.

Review: Treatment Recommendations for Biological Disasters

By April 17, 2018

The Centers for Disease Control and Prevention (CDC) classifies key biological agents into three categories: A, B, and C.

Treatment for Smallpox Gets FDA Priority Review

By February 07, 2018

The treatment was developed under the FDA's 'Animal Rule'; where efficacy is determined in animal studies and human studies determine safety and appropriate dosing. The FDA have stated a target action date for TPOXX of August 8, 2018.